HC Wainwright & Co. Initiates Coverage On Atossa Therapeutics With Buy Rating, Announces Price Target of $4
HC Wainwright & Co. Initiates Coverage On Atossa Therapeutics With Buy Rating, Announces Price Target of $4
HC Wainwright & Co.以買入評級啓動對Atossa Therapeutics的報道，宣佈目標股價爲4美元
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $4.
HC Wainwright & Co. 分析師艾米麗·博德納爾開始對Atossa Therapeutics（納斯達克股票代碼：ATOS）進行報道，評級爲買入，並宣佈目標股價爲4美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。